Qiagen and Roche this week each reported spikes in molecular diagnostics sales in 2010, although Roche reported flat sales for its applied science group.

For the fourth quarter of 2010, Qiagen's molecular diagnostics sales increased 7 percent on a constant exchange rate basis over 2009, primarily due to its infectious disease testing portfolio. Meantime, full-year 2010 molecular diagnostics sales rose 14 percent on a constant exchange rate basis over 2009. Qiagen said that molecular diagnostics comprises 48 percent of the company's total sales.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.